Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,596

Document Document Title
WO/2019/024920A1
The present disclosure provides methods of preparing cholic acid, deoxycholic acid, or chenodeoxycholic acid, an ester thereof, or a pharmaceutically or cosmetically acceptable salt thereof, and novel and useful synthetic intermediates, ...  
WO/2019/020067A1
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and the relevant intermediates. In particular, the present invention relates to a method for...  
WO/2019/021122A2
The present invention relates to novel Liver X Receptor (LXR) modulators, their use in diagnostic and therapy, more particularly in the treatment of diseases associated with LXR, such as cancer, inflammation, metabolic and autoimmune dis...  
WO/2019/023103A1
The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.  
WO/2019/015914A1
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) hydrogenation of the double bond and reductive opening of the epoxide of a compound of formula (II) or a salt or solvate t...  
WO/2018/234540A1
The present invention relates to a cocrystal of beta-sitosterol or a pharmaceutically acceptable ester thereof or an edible acceptable ester thereof and an organic carboxylic acid coformer, an hydrate crystal form of beta-sitosterol havi...  
WO/2018/227940A1
A method for preparing ursodeoxycholic acid via a chemical-enzymatic process, comprising: adding hyodeoxycholic acid to a first organic solvent, and oxidising under the effect of an oxidising agent to obtain 6-oxo-lithocholic acid; addin...  
WO/2018/223836A1
The present invention relates to a novel crystal form of a compound (I), a method for preparing same, and an application. Crystal form CS3, crystal form CS2, crystal form CS5, and crystal form CS8 of the compound (I) provided by the pres...  
WO/2018/226724A1
The present application relates to methods of treating or preventing an eye disease (e.g., a diabetic eye disease) in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of the application.  
WO/2018/221479A1
The purpose of the present invention is to provide a fluorescent substrate for a transporter, the fluorescent substrate maintaining high transport performance while being unlikely to be quenched and exhibiting strong fluorescent intensit...  
WO/2018/218281A1
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.  
WO/2018/220513A1
The invention relates to an improved process for the preparation of compound of formula (A), which is an intermediate in the preparation of Obeticholic acid or its analogous compounds thereof.  
WO/2018/222701A1
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...  
WO/2018/211413A1
The invention of the present application relates to crystalline forms of obeticholic acid and process for preparation thereof. Specifically, the invention of present application relates to crystalline forms VD1, VD2, VD3, VD4 and VD5 of ...  
WO/2018/213055A1
Oxysterol-statin compounds and methods of synthesizing the same are provided for use in promoting osteogenesis, osteoinduction and/or osteoconduction. Methods of synthesizing in a single container OXY133-statin compounds having high yiel...  
WO/2018/201516A1
A compound and an application thereof for treatment of cataract. The structural formula of the compound is as shown in formula I. The compound of formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof, can be used to...  
WO/2018/194253A1
A method for biological tissue transparency using an agent for biological tissue transparency containing CHAPS enables fast transparency without tissue degeneration.  
WO/2018/194426A1
The present invention provides a method for preparing a bile acid derivative by using a continuous flow reaction. When a bile acid derivative is synthesized using a continuous flow reaction, according to the present invention, the reacti...  
WO/2018/165269A2
The crystalline forms of obeticholic acid and methods of preparation and use thereof are described.  
WO/2018/164715A1
The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention.  
WO/2018/146641A1
The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides ...  
WO/2018/137683A1
Disclosed are a lanosterol prodrug compound, a pharmaceutically acceptable salt and an isomer thereof, and a pharmaceutical composition comprising the lanosterol prodrug compound and the use thereof in the preparation of a drug for treat...  
WO/2018/135699A1
The present invention provides a novel ergostenol glycoside derivative. The ergostenol and the glycoside derivative thereof according to the present invention suppresses the production of chemokines increasing according to the skin infla...  
WO/2018/085623A1
Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method...  
WO/2018/075698A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are...  
WO/2018/075699A1
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are con...  
WO/2018/064755A1
A transfection reagent composition comprising: 30-60MOL% of an cationic lipid, or pharmaceutical acceptable salt thereof; 10-60 MOL% structural lipid; a sterol and 0.1 to about 10MOL% of a stabilizing agent is provided. The reagent is pa...  
WO/2018/064649A1
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...  
WO/2018/059241A1
Disclosed are an extract with a detoxification pharmaceutical effect and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH...  
WO/2018/054300A1
Provided is a crystalline form cholic acid derivative free alkali, a preparation method therefor and an application. The chemical name of the cholic acid derivative free alkali is (5R)-5-((2R)-2-((3R,5S,6R,7R,10S,13R)-6-ethyl-3,7-dihydro...  
WO/2018/050815A1
The present invention relates to a compound of formula (I), in which R' represents a -(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group com...  
WO/2018/050814A1
The present invention relates to a compound of formula (I), in which R' represents a –(CRaRb)n-X-(CRcRd)m-[Y-(CReRf)o]t-NR9R10 group, and X and Y independently represent a -NR11- group, an –O- group or a divalent heterocyclic group c...  
WO/2018/026837A1
Compositions comprising oxygenated cholesterol sulfates (OCS) are provided. The OCS is, for example, 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or 5-cholesten, 3, 25-diol, disulfate (25HCDS). The compositions may be used to prevent and/o...  
WO/2018/013613A1
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...  
WO/2018/010651A1
The present invention relates to a method for manufacturing an obeticholic acid and an intermediate thereof. The invention specifically relates to a method for manufacturing a compound represented by formula V. The method comprises: usin...  
WO/2018/009867A1
Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, and R6, R11a, and R11b are as defined herein. Compounds of the present invention...  
WO/2018/002897A1
The present invention concerns compounds having formula (I) and compositions thereof with a pharmacologically acceptable excipient and uses thereof as a medicament, in particular for the treatment and/or prevention of a disorder selected...  
WO/2017/211820A1
The present invention relates to new and improved processes for the preparation of deoxycholic acid (DCA) and pharmaceutically acceptable salts thereof, as well as to novel intermediates useful for the preparation of DCA and pharmaceutic...  
WO/2017/207648A1
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) olefination of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (III) or a salt or ...  
WO/2017/208165A1
The invention of the present application relates to the process for the preparation of intermediates of obeticholic acid and their conversion to obeticholic acid. The process involves the conversion of compound of formula (VI) to compoun...  
WO/2017/199036A1
The invention relates to a process for preparing a compound of general formula (la): wherein R2, Y, R4and R5are as defined herein, wherein the epoxidation is conducted using an oxidant and methyltrioxorhenium as a catalyst (MeReO3). The ...  
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/190420A1
A mogrol derivative monomer (4) having broad spectrum antitumor efficacy; the monomer is superior in terms of both activity and efficacy than structurally similar and commercially available antitumor medicament/healthcare product Rg3, al...  
WO/2017/190421A1
Provided in the present invention is a novel mogrol derivative monomer (4), which can be prepared into a medicament for use in treating and/or preventing different cancers and/or tumors, can also be prepared into a healthcare product for...  
WO/2017/190422A1
A synthesis method for a composition comprising a mogrol derivative monomer (3) and a mogrol derivative monomer (4), compared with an existing method for synthesizing the mogrol derivative monomer (3), the present synthesis method is sim...  
WO/2017/187343A3
An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.  
WO/2017/189561A1
The present disclosure provides compositions comprising 25-hydroxycholesterol, derivatives and prodrugs thereof, and methods of use thereof. Specifically, disclosed herein are methods of decreasing neuronal cell death.  
WO/2017/187343A2
An oxysterol or oxysterol-like compound is provided, which finds use in treating and/or targeting cancer.  
WO/2017/186135A1
Disclosed in the present invention are a compound and an application thereof for the treatment of cataracts. The structural formula of the compound is shown in formula I. The compound shown in formula I, a prodrug thereof, or a pharmaceu...  

Matches 1 - 50 out of 3,596